Medi-CapsBOM:523144 -7.29%46 EBITDA Margin % is 103.02% as of Mar. 2026, which is 1333% above its 10-year median of 7.19. GuruFocus rates BOM:523144 with a GF Score™ of 46/100 and a GF Value™ of ₹20.10 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,745 Real Estate companies, Medi-Caps ranks worse than 81.66% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medi-Caps's EBITDA for the
three
months ended in Mar. 2026 was ₹35.3 Mil. Medi-Caps's Revenue for the
three
months ended in Mar. 2026 was ₹34.2 Mil. Therefore, Medi-Caps's EBITDA margin for the quarter that ended in Mar. 2026 was 103.02%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medi-Caps EBITDA Margin % Related Terms
Medi-Caps EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medi-Caps's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Real Estate - Diversified subindustry, Medi-Caps's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medi-Caps EBITDA Margin % vs Real Estate Industry
For the Real Estate industry and Real Estate sector, Medi-Caps's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medi-Caps's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medi-Caps (BOM:523144) has a EBITDA Margin % of 103.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medi-Caps and its competitors. This is 1333% above median its historical median of 7.19. According to the industry distribution chart, Medi-Caps ranks #1425 out of 1745 companies in the Real Estate industry, placing it in the top 81.7%.
Is Medi-Caps' EBITDA Margin % too high?
Medi-Caps' current EBITDA Margin % of 103.02% is 1333% above median its 10-year median of 7.19. The Real Estate industry median EBITDA Margin % is 21.62. Medi-Caps' value of 103.02% is 376.5% above this industry median. Based on the distribution chart, Medi-Caps ranks #1425 out of 1745 companies in the Real Estate industry, which is in the bottom quartile relative to peers. Overall, Medi-Caps has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medi-Caps' EBITDA Margin % compare to competitors?
According to the Real Estate industry distribution chart, Medi-Caps ranks #1425 out of 1745 companies for EBITDA Margin %. This places Medi-Caps in the lower half of its industry. The industry median EBITDA Margin % is 21.62. Medi-Caps' value of 103.02% is 376.5% above this benchmark. While the company's 10-year median is 7.19 vs. the industry median of 21.62, Medi-Caps has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Real Estate company?
The median EBITDA Margin % among Real Estate companies is 21.62, based on 1,745 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medi-Caps's current EBITDA Margin % of 103.02% is 376.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medi-Caps and its competitors. For the Real Estate industry, the median EBITDA Margin % is 21.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medi-Caps's current EBITDA Margin % is 103.02%, which is 1333% above median its own 10-year median of 7.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medi-Caps stock overvalued right now?
Based on GuruFocus' analysis, Medi-Caps (BOM:523144) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹20.10, compared to a current price of ₹25.93 — trading 29% above its estimated fair value. The current EBITDA Margin % is 103.02%, which is 1333% above median its 10-year median of 7.19 and 376.5% above the Real Estate industry median of 21.62. Medi-Caps' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medi-Caps (BOM:523144), the current EBITDA Margin % is 103.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medi-Caps (BOM:523144) Overvalued in 2026?
Based on GuruFocus' analysis, Medi-Caps stock appears to be overvalued.
The current stock price of ₹25.93 is trading 29% above its estimated GF Value™ of ₹20.10.
GuruFocus considers Medi-Caps to be Modestly Overvalued.
Key valuation signals for BOM:523144:
EBITDA Margin %: 103.02% (1333% above median its 10-year median of 7.19)
GF Value™: ₹20.10 vs. price of ₹25.93 (29% above fair value)
Industry Position: 376.5% above the Real Estate median (#1425 of 1745)
No single metric tells the full story. See the BOM:523144 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medi-Caps Ltd is an India-based company engaged in the real estate business witch city centric developments by way of Strategic Land acquisition and developing the residential and commercial properties. Its project include Medicaps Business Park. The group has two segments namely, the Pharma Division, and the Real Estate Division. The majority of its revenue is generated from the Pharma Division.
46GF Score
Get the complete analysis for BOM:523144
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:523144 has been successfully added to your 
